[Polychemotherapy of advanced soft tissue sarcomas with 4'-epi-doxorubicin (4'-Epi-DX) and cisplatin (DDP)].
34 patients with locally advanced or metastatic soft tissue sarcoma were treated with 4'-epi-adriamycin (4'-Epi-DX: 45 mg/m2 day 1 + 2) and cisplatinum (DDP: 90 mg/m2 day 2). If leukocyte- or plateletnadirs during the previous interval were above 2,000/mm3 or 70,000/mm3 the dose of 4'-Epi-DX was escalated for 5 mg/m2 per treatment day. One patient died tumor-related soon after the first treatment cycle. In 33 evaluable patients 4 (12%) complete remissions, 10 (30%) partial remissions and 15 (46%) no changes were observed. 4 patients (12%) had primary progressive disease under treatment. In 6 patients treatment was stopped because of side effects: 4 intractable nausea and vomiting, 1 ototoxicity, 1 supposed cardiomyopathy. Hematotoxicity was not a limiting factor in this treatment regimen.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
D015251:Epirubicin; D004317:Doxorubicin; D002945:Cisplatin
Polychemotherapie fortgeschrittener Weichteilsarkome mit 4'-Epi-Doxorubicin (4'-Epi-DX) und Cisplatin (DDP).